What will be Candel Therapeutics' market cap by end of 2025?
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $5 billion • 25%
More than $5 billion • 25%
Financial reports and stock market data
Candel Therapeutics' CAN-2409 Succeeds in Phase 3 Prostate Cancer Trial, Shares Soar
Dec 11, 2024, 12:48 PM
Candel Therapeutics announced that its experimental immunotherapy, CAN-2409, met the primary endpoint in a Phase 3 trial for prostate cancer, showing significantly improved disease-free survival. Following the announcement, the company's shares more than doubled in value in premarket trading. CAN-2409 is an oncolytic virus designed to stimulate the immune system to attack cancer cells. The trial's success marks a significant milestone for Candel Therapeutics, potentially paving the way for further development and regulatory approval of the treatment.
View original story
$15 billion • 25%
$20 billion • 25%
$25 billion • 25%
Other • 25%
$10.2B to $15B • 25%
Above $15B • 25%
Below $5B • 25%
$5B to $10.2B • 25%
Less than $2 billion • 25%
$4 billion to $6 billion • 25%
More than $6 billion • 25%
$2 billion to $4 billion • 25%
$8 billion to $10 billion • 25%
Under $8 billion • 25%
Over $12 billion • 25%
$10 billion to $12 billion • 25%
Below $100 million • 25%
Above $300 million • 25%
$200 million to $300 million • 25%
$100 million to $200 million • 25%
Top 100 • 25%
Below Top 200 • 25%
Top 50 • 25%
Top 200 • 25%
Increased by over 10% • 25%
Decreased by over 10% • 25%
Remained within 10% range • 25%
No significant change • 25%
Decreases by more than 10% • 25%
Increases by more than 10% • 25%
Other • 25%
Remains within 10% of current share • 25%
Above $300M • 25%
$100M to $200M • 25%
Below $100M • 25%
$200M to $300M • 25%
Roche • 25%
Daiichi Sankyo • 25%
Pfizer • 25%
AstraZeneca • 25%
No • 50%
Yes • 50%
Above $4.5 trillion • 25%
Below $3.5 trillion • 25%
$4 trillion to $4.5 trillion • 25%
$3.5 trillion to $4 trillion • 25%
No • 50%
Yes • 50%
Initiation of Phase 4 trial • 25%
Regulatory approval in Europe • 25%
Launch of a new indication study • 25%
No major milestone announced • 25%